About Aptuit INDiGO™
Aptuit INDiGO™ accelerates early drug candidates, even those that are poorly bioavailable, into the clinic by reducing time from API to IND submission to 26 weeks, or even less under certain circumstances. Accelerated development is achieved by tightly integrating traditional pre-formulation, drug substance, preclinical, drug product, clinical trial materials and analytical silos into a single project. Aptuit INDiGO™ projects are managed by a veteran, dedicated project manager and staffed by professionals with experience spanning the drug development process. This service may be used for small and large, protein-based drugs and can accommodate varied client needs.

Aptuit INDiGO™: Addressing an Industry Need
Although the industry has seen an increase in overall R&D spending the number of novel compounds making it to market has decreased. Drug innovators are faced with wading through thousands of compounds in order to get on to market, spending an average of 10 years in drug development. By more rapidly advancing a potential compound into man, drug developers can make critical portfolio decisions, potentially saving millions of dollars and years in development. Also, technological advances such as high throughput screening (HTS) have offered drug developers a seemingly endless number of candidates to investigate. However, HTS favors higher molecular weight compounds which tend to be larger, less soluble and less bioavailable, increasing the challenges faced in getting a drug to market.

Aptuit INDiGO™ offers a solution to the bioavailability challenge in the early development phase. Aptuit’s accelerated approach can also be applied to molecules with acceptable solubility. Aptuit provides all of the Aptuit INDiGO™ elements in-house, ensuring expert-to-expert handoff and tight project management within our world class, global facilities. Our ability to integrate these early development components is unprecedented and still unmatched in the industry. Aptuit’s capabilities combine to deliver superior timelines that will help accelerate our client’s drug development and maximize our clients’ investments and patent portfolio.

Why choose Aptuit INDiGO™?

• Get drug candidates, including poorly bioavailable drugs, into human trials quickly
• Tailor your program to meet your needs, with or without API supply
• Leverage integrated in-house capabilities, including world-class preclinical toxicology, clinical supplies and regulatory documentation and IND preparation support services
• Achieve reduced timelines and accelerated time to submission
• Benefit from streamlined scientist-to-scientist communication
• Use quality-by-design approach
• Ensure the best possible approaches for poorly soluble drugs including amorphous dispersion in capsule
• Leverage first class solid state chemistry expertise
• Take advantage of intellectual property support capabilities

More Information about Aptuit INDiGO™
Interested in how we can help you get your drug candidate into the clinic quickly?

Download Aptuit INDiGO™ Fact Sheets by following the links on this page

Call one of our Aptuit INDiGO ™ specialists at

+1 816 767 3900 North America
+44 131 451 2451 Europe

Or email your question to info@aptuit.com

Meet with an Aptuit INDiGO ™ specialist at one of our upcoming conferences